COH-SR4 reduces body weight, improves glycemic control and prevents hepatic steatosis in high fat diet-induced obese mice

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Figarola, James Lester ^a   Singhal, Preeti ^a   Rahbar, Samuel ^a   Gugiu, Bogdan Gabriel ^a   Awasthi, Sanjay ^a   Singhal, Sharad S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(3,5 DICHLOROPHENYL)UREA; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE 1; ADIPONECTIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; CARNITINE PALMITOYLTRANSFERASE 1A; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; LIVER ENZYME; LIVER KINASE B1; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 1; PHOSPHOTRANSFERASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA DERIVATIVE; 1,3-BIS(3,5-DICHLOROPHENYL)UREA; ADIPOCYTOKINE; CARBANILAMIDE DERIVATIVE; GLUCOSE BLOOD LEVEL;

ACACA GENE; ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CPT1A GENE; DRUG MECHANISM; EPIDIDYMIS FAT; FASN GENE; FATTY LIVER; FOOD INTAKE; G6PC GENE; GENE; GENE REPRESSION; GLUCONEOGENESIS; GLYCEMIC CONTROL; HMGCR GENE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIPID DIET; LIPOGENESIS; MALE; MOUSE; NONHUMAN; OBESITY; PPARG GENE; SCD1 GENE; SREBF1 GENE; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; DYSLIPIDEMIAS; ENZYME ACTIVATION; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; HYPERTROPHY; LIVER; METABOLISM; MOUSE MUTANT; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADIPOKINES; ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CELL LINE, TUMOR; DIET, HIGH-FAT; DYSLIPIDEMIAS; ENZYME ACTIVATION; HUMANS; HYPERTROPHY; LIPOGENESIS; LIVER; MALE; MICE; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; TRIGLYCERIDES;

EID: 84893431857     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083801     Document Type: Article

References (51)

1. World Health Organization Fact Sheet N°311: Obesity and overweight. Available: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 2013 Aug 7.
2. Grundy SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595-2600.
3. Garg SK, Maurer H, Reed K, Selagamsetty R (2013) Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab DOI:10.1111/dom.12124 [Epub ahead of print].
4. Jo J, Gavrilova O, Pack S, Jou W, Mullen S, et al. (2009) Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol 5:e1000324.
5. Taube A, Schlich R, Sell H, Eckardt K, Eckel J (2012) Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol. 302:H2148-H165.
6. Harvey AE, Lashinger LM, Hursting SD (2011) The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sc 1229:45-52.
7. Hardie DG (2011) Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 93:891S-896S.
8. Carling D, Mayer FV, Sanders MJ, Gamblin SJ (2011) AMP-activated protein kinase: nature's energy sensor. Nat Chem Biol 7:512-518.
9. Henin N, Vincent MF, Gruber HE, Van den Berghe G (1995) Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 9:541-546.
10. Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, et al. (2009) AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 196:81-98.
11. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, et al. (2012) AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res 53:2490-2514.
12. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13:376-388.
13. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K (2002) Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2776:3829-3835. (Pubitemid 34968632)
14. Villena JA, Viollet B, Andreelli F, Kahn A, Vaulont S, et al. (2004) Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes 53:2242-2249. (Pubitemid 39145577)
15. Zhang W, Zhang X, Wang H, Guo X, Li H, et al. (2012) AMP-activated protein kinase a1 protects against diet-induced insulin resistance and obesity. Diabetes 61:3114-3125.
16. Fogarty S, Hardie DG (2009) Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804:581-591.
17. Russo GL, Russo M, Ungaro P (2013) AMP-activated protein kinase: A target for old drugs against diabetes and cancer. Biochem Pharmacol 86:339-350.
18. Hardie DG (2013) AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62:2164-2172.
19. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174. (Pubitemid 32995375)
20. Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, et al. (2009) Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 52:723-732.
21. Do GM, Jung UJ, Park HJ, Kwon EY, Jeon SM, et al. (2012) Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res 6:1282-1291.
22. Um MY, Hwang KH, Ahn J, Ha TY (2013) Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 113:152-157.
23. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, et al. (2009) Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 296:E812-E819.
24. Lee JW, Choe SS, Jang H, Kim J, Jeong HW, et al. (2012) AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity. J Lipid Res 53:1277-1286.
25. Figarola JL, Weng Y, Lincoln C, Horne D, Rahbar S (2012) Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis. Invest New Drugs 30:1413-1425.
26. Singhal SS, Figarola J, Singhal J, Leake K, Nagaprashantha L, et al. (2012) 1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma. Biochem Pharmacol 84:1419-1427.
27. Figarola JL, Rahbar S (2013) Small molecule COH-SR4 inhibits adipocyte differentiation via AMPK activation. Int J Mol Med 31:1166-1176.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta deltaC(T)) method. Methods 25:402-408. (Pubitemid 34164012)
29. Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14:741-751.
30. Collins S, Martin TL, Surwit RS, Robidoux J (2004) Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81:243-248. (Pubitemid 38670090)
31. Winzell MS, Ahrén B (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53:S215-S219.
32. Boden G, Laakso M (2004) Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 27:2253-2259. (Pubitemid 39167198)
33. Parekh S, Anania A (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132:2191-2207. (Pubitemid 46693752)
34. Wakil SJ, Abu-Elheiga LA (2009) Fatty acid metabolism: target for metabolic syndrome. J Lipid Res 50:S138-S143.
35. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, et al. (2002) Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol 92:2475-2482. (Pubitemid 34666373)
36. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838. (Pubitemid 351364588)
37. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR, et al. (2001) Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50:1076-1082. (Pubitemid 32374538)
38. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, et al. (2008) Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29:698-706. (Pubitemid 351799479)
39. Polak P, Cybulski N, Feige JN, Auwerx J, Rüegg MA, et al. (2008) Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 8:399-410.
40. Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, et al. (2009) Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J Pharmacol Sci 109:496-503.
41. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, et al. (2006) Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147:2432-2441.
42. Viollet B, Andreelli F, Jørgensen SB, Perrin C, Geloen A, et al. (2003) The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111:91-98. (Pubitemid 36134852)
43. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, et al. (2005) Shortterm overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54:1331-1339. (Pubitemid 40586661)
44. Shirai T, Inoue E, Ishimi Y, Yamauchi J (2011) AICAR response element binding protein (AREBP), a key modulator of hepatic glucose production regulated by AMPK in vivo. Biochem Biophys Res Commun 414:287-291.
45. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, et al. (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11:554-565.
46. Singhal SS, Figarola J, Singhal J, Nagaprashantha L, Berz D, et al. (2013) Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression. Biochem Pharmacol (in-press).
47. Choi YK, Park KG (2013) Metabolic roles of AMPK and metformin in cancer cells. Mol Cells 36:279-287.
48. Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, et al. (2010) Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem 58:1584-1592.
49. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, et al. (2012) Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 83:385-394.
50. Jeon SM, Hay N (2012) The dark face of AMPK as an essential tumor promoter. Cell Logist 2:197-202.
51. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, et al. (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569-574. (Pubitemid 38480541)